-
T.
Hideshima,
D.
Chauhan,
Y.
Shima,
N.
Raje,
F.
Davies,
Y.
Tai,
S.
Treon,
B.
Lin,
R.
Schlossman,
P.
Richardson,
G.
Muller,
D.
Stirling,
K.
Anderson
(2000)
Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.
Blood, 96 9
-
O.
Cope,
S.
Wyman
(1948)
Multiple myeloma.
The New England journal of medicine, 239 10
-
A.
Palumbo,
M.
Cavo,
S.
Bringhen,
E.
Zamagni,
A.
Romano,
F.
Patriarca,
D.
Rossi,
F.
Gentilini,
C.
Crippa,
M.
Galli,
C.
Nozzoli,
R.
Ria,
R.
Marasca,
V.
Montefusco,
L.
Baldini,
F.
Elice,
V.
Callea,
S.
Pulini,
A.
Carella,
R.
Zambello,
G.
Benevolo,
V.
Magarotto,
P.
Tacchetti,
N.
Pescosta,
C.
Cellini,
C.
Polloni,
A.
Evangelista,
T.
Caravita,
F.
Morabito,
M.
Offidani,
P.
Tosi,
M.
Boccadoro
(2011)
Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 8
-
(2011)
Multiple myeloma
N Engl J Med, 364
-
P.
McCarthy,
K.
Owzar,
K.
Anderson,
C.
Hofmeister,
H.
Hassoun,
D.
Hurd,
E.
Stadtmauer,
S.
Giralt,
V.
Hárs,
C.
Linker,
Ecog
Calgb,
Bmt-Ctn
(2010)
Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104.
Journal of Clinical Oncology, 28
-
Case report: Response to lenalidomide in a patient with refractory MM and extramedullary plasmacytomas [abstract]
-
A.
Chanan-Khan,
Zhinuan
Yu,
D.
Weber,
Christine
Chen,
R.
Niesvizky,
A.
Spencer,
M.
Attal,
A.
Belch,
M.
Prince,
Marta
Olesnyckyj,
R.
Knight,
J.
Zeldis,
M.
Dimopoulos
(2006)
Lenalidomide (L) in Combination with Dexamethasone (D) Significantly Improves Time to Progression (TTP) in Non-Stem Cell Transplant Patients (pts) with Relapsed or Refractory (rel/ref) Multiple Myeloma (MM): Analysis from MM-009 and MM-010 Randomized Phase III Clinical Trials.
Blood, 108
-
M.
Dimopoulos,
Christine
Chen,
A.
Spencer,
R.
Niesvizky,
M.
Attal,
E.
Stadtmauer,
Maria
Petrucci,
Zhinuan
Yu,
Marta
Olesnyckyj,
J.
Zeldis,
R.
Knight,
D.
Weber
(2009)
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma
Leukemia, 23
-
F.
Patriarca,
Simonetta
Prosdocimo,
V.
Tomadini,
A.
Vasciaveo,
B.
Bruno,
R.
Fanin
(2005)
Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation.
Haematologica, 90 2
-
J.
San-Miguel,
M.
Dimopoulos,
E.
Stadtmauer,
S.
Rajkumar,
D.
Siegel,
M.
Bravo,
Marta
Olesnyckyj,
R.
Knight,
J.
Zeldis,
J.
Harousseau,
D.
Weber
(2011)
Effects of lenalidomide and dexamethasone treatment duration on survival in patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone.
Clinical lymphoma, myeloma & leukemia, 11 1
-
A.
Alegre,
Albert
Oriol-Rocafiguera,
J.
García-Laraña,
M.
Mateos,
A.
Sureda,
C.
Chamorro,
M.
Cibeira,
R.
Knight,
B.
Rosettani
(2010)
Safety, Efficacy, and Quality-of-Life Study of Lenalidomide Plus Dexamethasone In Previously Treated Patients with Multiple Myeloma: The Spanish Experience
Blood, 116
-
A.
Gandhi,
J.
Kang,
L.
Capone,
A.
Parton,
L.
Wu,
L.
Zhang,
D.
Mendy,
A.
López-Girona,
T.
Tran,
L.
Sapinoso,
W.
Fang,
S.
Xu,
G.
Hampton,
J.
Bartlett,
P.
Schafer
(2010)
Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.
Current cancer drug targets, 10 2
-
L.
Corral,
P.
Haslett,
G.
Muller,
R.
Chen,
L.
Wong,
C.
Ocampo,
R.
Patterson,
D.
Stirling,
G.
Kaplan
(1999)
Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.
Journal of immunology, 163 1
-
N.
Dubrawsky
(1989)
Cancer statistics
CA: A Cancer Journal for Clinicians, 39
-
M.
Dimopoulos,
A.
Spencer,
M.
Attal,
H.
Prince,
J.
Harousseau,
A.
Dmoszyńska,
J.
Miguel,
A.
Hellmann,
T.
Facon,
R.
Foà,
A.
Corso,
Z.
Masliak,
Marta
Olesnyckyj,
Zhinuan
Yu,
J.
Patin,
J.
Zeldis,
R.
Knight
(2007)
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.
The New England journal of medicine, 357 21
-
M.
Delforge,
T.
Facon,
M.
Bravo,
M.
Dimopoulos
(2009)
Lenalidomide plus Dexamethasone Has Similar Tolerability and Efficacy in Treatment of Relapsed/Refractory Multiple Myeloma Patients with or without History of Neuropathy.
Blood, 114
-
M.
Krauth,
A.
Bankier,
P.
Valent,
P.
Kalhs,
J.
Drach
(2005)
Sustained remission including marked regression of a paravertebral plasmacytoma in a patient with heavily pretreated, relapsed multiple myeloma after treatment with bortezomib.
Leukemia research, 29 12
-
E.
Stadtmauer,
D.
Weber,
R.
Niesvizky,
A.
Belch,
M.
Prince,
J.
Miguel,
T.
Facon,
Marta
Olesnyckyj,
Zhinuan
Yu,
J.
Zeldis,
R.
Knight,
M.
Dimopoulos
(2009)
Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma
European Journal of Haematology, 82
-
S.
Rajkumar,
S.
Jacobus,
N.
Callander,
R.
Fonseca,
D.
Vesole,
M.
Williams,
R.
Abonour,
D.
Siegel,
M.
Katz,
P.
Greipp
(2010)
Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial.
The Lancet. Oncology, 11 1
-
C.
Bennett,
C.
Angelotta,
P.
Yarnold,
A.
Evens,
J.
Zonder,
D.
Raisch,
P.
Richardson
(2006)
Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.
JAMA, 296 21
-
(2008)
Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
Blood, 112
-
Shaji
Kumar,
S.
Rajkumar,
A.
Dispenzieri,
M.
Lacy,
S.
Hayman,
F.
Buadi,
S.
Zeldenrust,
D.
Dingli,
S.
Russell,
J.
Lust,
P.
Greipp,
R.
Kyle,
M.
Gertz
(2008)
Improved survival in multiple myeloma and the impact of novel therapies.
Blood, 111 5
-
P.
Richardson,
E.
Blood,
C.
Mitsiades,
S.
Jagannath,
S.
Zeldenrust,
M.
Alsina,
R.
Schlossman,
S.
Rajkumar,
K.
Desikan,
T.
Hideshima,
Nikhil
Munshi,
Kathleen
Kelly-Colson,
D.
Doss,
M.
Mckenney,
S.
Gorelik,
D.
Warren,
A.
Freeman,
Rebecca
Rich,
A.
Wu,
Marta
Olesnyckyj,
K.
Wride,
W.
Dalton,
J.
Zeldis,
R.
Knight,
E.
Weller,
K.
Anderson
(2006)
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.
Blood, 108 10
-
Clinical Medicine Insights: Oncology
-
V.
Kotla,
Swati
Goel,
Sangeeta
Nischal,
Christoph
Heuck,
Kumar
Vivek,
Bhaskar
Das,
Amit
Verma
(2009)
Mechanism of action of lenalidomide in hematological malignancies
Journal of Hematology & Oncology, 2
-
J.
Calvo-Villas,
A.
Alegre,
Carmen
Calle,
M.
Hernandez,
R.
García-Sánchez,
G.
Ramirez
(2011)
Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma
European Journal of Haematology, 87
-
H.
Brenner,
A.
Gondos,
D.
Pulte
(2008)
Recent major improvement in long-term survival of younger patients with multiple myeloma.
Blood, 111 5
-
A.
Palumbo,
S.
Rajkumar,
M.
Dimopoulos,
P.
Richardson,
J.
Miguel,
B.
Barlogie,
J.
Harousseau,
J.
Zonder,
M.
Cavo,
M.
Zangari,
M.
Attal,
A.
Belch,
S.
Knop,
D.
Joshua,
O.
Sezer,
H.
Ludwig,
D.
Vesole,
J.
Bladé,
R.
Kyle,
J.
Westin,
D.
Weber,
S.
Bringhen,
R.
Niesvizky,
A.
Waage,
M.
Lilienfeld-Toal,
S.
Lonial,
G.
Morgan,
R.
Orlowski,
K.
Shimizu,
K.
Anderson,
M.
Boccadoro,
B.
Durie,
P.
Sonneveld,
M.
Hussein
(2008)
Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma
Leukemia, 22
-
P.
Richardson,
R.
Schlossman,
E.
Weller,
T.
Hideshima,
C.
Mitsiades,
F.
Davies,
R.
LeBlanc,
L.
Catley,
D.
Doss,
K.
Kelly,
M.
Mckenney,
Julie
Mechlowicz,
A.
Freeman,
Reggie
Deocampo,
Rebecca
Rich,
J.
Ryoo,
D.
Chauhan,
Kathe
Balinski,
J.
Zeldis,
K.
Anderson
(2002)
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.
Blood, 100 9
-
A.
Palumbo,
M.
Delforge,
John
Catalano,
Roman
Hájek,
M.
Kropff,
Maria
Petrucci,
Zhinuan
Yu,
Jay
Mei,
M.
Dimopoulos
(2011)
Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
D.
Weber,
Christine
Chen,
R.
Niesvizky,
Michael
Wang,
A.
Belch,
E.
Stadtmauer,
D.
Siegel,
I.
Borrello,
S.
Rajkumar,
A.
Chanan-Khan,
S.
Lonial,
Zhinuan
Yu,
J.
Patin,
Marta
Olesnyckyj,
J.
Zeldis,
R.
Knight
(2007)
Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.
The New England journal of medicine, 357 21
-
J.
Marriott,
I.
Clarke,
K.
Dredge,
G.
Muller,
D.
Stirling,
A.
Dalgleish
(2002)
Thalidomide and its analogues have distinct and opposing effects on TNF‐α and TNFR2 during co‐stimulation of both CD4+ and CD8+ T cells
Clinical & Experimental Immunology, 130
-
Shaji
Kumar,
T.
Therneau,
M.
Gertz,
M.
Lacy,
A.
Dispenzieri,
S.
Rajkumar,
R.
Fonseca,
T.
Witzig,
J.
Lust,
D.
Larson,
R.
Kyle,
P.
Greipp
(2004)
Clinical course of patients with relapsed multiple myeloma.
Mayo Clinic proceedings, 79 7
-
A.
Alegre,
B.
Aguado,
P.
Giraldo,
E.
Ríos,
A.
Cánovas,
Á.
Ibáñez,
I.
Castillo,
M.
Hernandez,
A.
Oriol,
L.
Palomera,
Juan
Rodríguez,
Florencia
Garcia,
J.
Calvo,
C.
Martínez-Chamorro,
J.
Serna,
J.
Lahuerta
(2011)
Lenalidomide is effective as salvage therapy in refractory or relapsed multiple myeloma: analysis of the Spanish Compassionate Use Registry in advanced patients
International Journal of Hematology, 93
-
A.
Palumbo
(2009)
Faculty Opinions recommendation of Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
-
L.
Rosiñol,
M.
Cibeira,
J.
Bladé,
J.
Esteve,
M.
Aymerich,
M.
Rozman,
M.
Segarra,
M.
Cid,
X.
Filella,
E.
Montserrat
(2004)
Extramedullary multiple myeloma escapes the effect of thalidomide.
Haematologica, 89 7
-
B.
Durie,
G.
Morgan,
J.
San-Miguel,
R.
Orlowski,
S.
Lonial,
R.
Niesvizky,
Z.
Yu,
K.
Anderson
(2011)
Long-term safety of lenalidomide (LEN) in relapsed/refractory multiple myeloma (RRMM) patients (Pts): Analysis of pooled data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
D.
Verhelle,
L.
Corral,
Kevin
Wong,
Jessica
Mueller,
L.
Parseval,
K.
Jensen-Pergakes,
P.
Schafer,
R.
Chen,
E.
Glezer,
Gregory
Ferguson,
A.
López-Girona,
G.
Muller,
H.
Brady,
Kyle
Chan
(2007)
Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.
Cancer research, 67 2
-
(2011)
Case report: Response to lenalidomide in a patient with refractory MM and extramedullary plasmacytomas [abstract]. 13th International Myeloma Workshop
-
M.
Dimopoulos,
R.
Orlowski,
R.
Niesvizky,
S.
Lonial,
N.
Brandenburg,
D.
Weber
(2011)
Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): Analysis of MM-009/010.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
M.
Attal,
V.
Lauwers,
G.
Marit,
D.
Caillot,
T.
Facon,
C.
Hulin,
P.
Moreau,
C.
Mathiot,
M.
Roussel,
C.
Payen,
H.
Avet-Loiseau,
J.
Harousseau
(2010)
Maintenance Treatment with Lenalidomide After Transplantation for MYELOMA: Final Analysis of the IFM 2005-02.
Blood, 116
-
J.
Bladé,
M.
Perales,
L.
Rosiñol,
M.
Tuset,
S.
Montoto,
J.
Esteve,
F.
Cobo,
Luis
Villela,
M.
Rafel,
B.
Nomdedeu,
E.
Montserrat
(2001)
Thalidomide in multiple myeloma: lack of response of soft‐tissue plasmacytomas
British Journal of Haematology, 113
-
A.
Palumbo,
M.
Dimopoulos,
J.
Miguel,
J.
Harousseau,
M.
Attal,
M.
Hussein,
S.
Knop,
H.
Ludwig,
M.
Lilienfeld-Toal,
P.
Sonneveld
(2009)
Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma.
Blood reviews, 23 2
-
M.
Dimopoulos,
A.
Palumbo,
M.
Attal,
M.
Beksaç,
F.
Davies,
M.
Delforge,
H.
Einsele,
R.
Hájek,
J.
Harousseau,
F.
Costa,
H.
Ludwig,
U.
Mellqvist,
G.
Morgan,
J.
San-Miguel,
S.
Zweegman,
P.
Sonneveld
(2011)
Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement
Leukemia, 25
-
H.
Brenner,
A.
Gondos,
D.
Pulte
(2008)
Expected long-term survival of patients diagnosed with multiple myeloma in 2006–2010
Haematologica, 94
-
(2008)
Country Fast Stats Available at: http://globocan.iarc.fr/factsheets/ populations/factsheet.asp?uno=968
-
P.
McCarthy,
K.
Owzar,
K.
Anderson,
C.
Hofmeister,
D.
Hurd,
H.
Hassoun,
S.
Giralt,
E.
Stadtmauer,
P.
Richardson,
D.
Weisdorf,
R.
Vij,
J.
Moreb,
N.
Callander,
K.
Besien,
T.
Gentile,
L.
Isola,
R.
Maziarz,
D.
Gabriel,
A.
Bashey,
H.
Landau,
T.
Martin,
M.
Qazilbash,
D.
Levitan,
B.
Mcclune,
V.
Hárs,
John
Postiglione,
Chen
Jiang,
E.
Bennett,
S.
Barry,
L.
Bressler,
M.
Kelly,
M.
Sexton,
C.
Rosenbaum,
H.
Parameswaran,
M.
Pasquini,
M.
Horowitz,
T.
Shea,
S.
Devine,
C.
Linker
(2010)
Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104
Blood, 116
-
S.
Vallet,
A.
Palumbo,
N.
Raje,
M.
Boccadoro,
K.
Anderson
(2008)
Thalidomide and lenalidomide: Mechanism-based potential drug combinations
Leukemia & Lymphoma, 49
-
J.
Harousseau,
M.
Dimopoulos,
Michael
Wang,
A.
Corso,
Christine
Chen,
M.
Attal,
A.
Spencer,
Zhinuan
Yu,
Marta
Olesnyckyj,
J.
Zeldis,
R.
Knight,
D.
Weber
(2010)
Better quality of response to lenalidomide plus dexamethasone is associated with improved clinical outcomes in patients with relapsed or refractory multiple myeloma
Haematologica, 95
-
E.
Kneppers,
H.
Lokhorst,
C.
Eeltink,
G.
Huls,
M.
Kersten,
J.
Koedam,
M.
Minnema,
M.
Oers,
R.
Raymakers,
M.
Schaafsma,
E.
Vellenga,
P.
Wijermans,
S.
Wittebol,
P.
Sonneveld,
S.
Zweegman
(2010)
Analysis of efficacy and prognostic factors of lenalidomide treatment as part of a Dutch compassionate use program.
Clinical lymphoma, myeloma & leukemia, 10 2
-
Rosiñol
Laura,
M.
Cibeira,
Carla
Uriburu,
S.
Yantorno,
O.
Salamero,
J.
Bladé,
E.
Montserrat
(2006)
Bortezomib: an effective agent in extramedullary disease in multiple myeloma
European Journal of Haematology, 76
-
K.
Dredge,
Rebecca
Horsfall,
S.
Robinson,
Ling-hua
Zhang,
L.
Lu,
Yang
Tang,
M.
Shirley,
G.
Muller,
P.
Schafer,
D.
Stirling,
A.
Dalgleish,
J.
Bartlett
(2005)
Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.
Microvascular research, 69 1-2
-
A.
Rossi,
T.
Mark,
D.
Jayabalan,
Paul
Christos,
Faiza
Zafar,
K.
Pekle,
T.
Shore,
R.
Pearse,
John
Leonard,
S.
Chen‐Kiang,
M.
Coleman,
R.
Niesvizky
(2011)
Incidence of second primary malignancies (SPM) after 6-years follow-up of continuous lenalidomide in first-line treatment of multiple myeloma (MM).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15_suppl
-
Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial
-
(2010)
A multicenter, single-arm, openlabel safety and quality of life study of lenalidomide plus dexamethasone in previously treated patients with multiple myeloma
Haematologica, 95
-
M.
Dimopoulos,
A.
Alegre,
E.
Stadtmauer,
H.
Goldschmidt,
J.
Zonder,
Carlos
Castro,
Z.
Masliak,
D.
Reece,
Marta
Olesnyckyj,
Zhinuan
Yu,
D.
Weber
(2010)
The efficacy and safety of lenalidomide plus dexamethasone in relapsed and/or refractory multiple myeloma patients with impaired renal function
Cancer, 116
-
N.
Mitsiades,
C.
Mitsiades,
V.
Poulaki,
D.
Chauhan,
P.
Richardson,
T.
Hideshima,
N.
Munshi,
S.
Treon,
K.
Anderson
(2002)
Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.
Blood, 99 12
-
F.
Davies,
N.
Raje,
T.
Hideshima,
S.
Lentzsch,
G.
Young,
Y.
Tai,
B.
Lin,
K.
Podar,
Deepak
Gupta,
D.
Chauhan,
S.
Treon,
P.
Richardson,
R.
Schlossman,
G.
Morgan,
G.
Muller,
D.
Stirling,
K.
Anderson
(2001)
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.
Blood, 98 1
-
A.
Jemal,
R.
Siegel,
Jiaquan
Xu,
Elizabeth
Ward
(2010)
Cancer Statistics, 2010
CA: A Cancer Journal for Clinicians, 60
-
(2009)
Revlimid (lenalidomide) prescribing information. Summit, NJ: Celgene Corporation Available at: http://www.revlimid.com/docs/ Revlimid-Full-PI.pdf
-
C.
Galustian,
Brendan
Meyer,
M.
Labarthe,
K.
Dredge,
Deborah
Klaschka,
J.
Henry,
S.
Todryk,
R.
Chen,
G.
Muller,
D.
Stirling,
P.
Schafer,
J.
Bartlett,
A.
Dalgleish
(2009)
The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells
Cancer Immunology, Immunotherapy, 58